17th Annual Ride for SickKids Returns August 10, 2025 Français
TORONTO, Aug. 6, 2025 /CNW/ - Over 600 motorcycle riders are expected to rev their engines for a cause that touches the hearts of thousands across Ontario. The 17th Annual Ride for SickKids is set to take place on Sunday, August 10, 2025, kicking off from North Maple Regional Park in Vaughan. This year's fundraising goal is $200,000, aimed at purchasing life-saving pediatric medical equipment and supporting the SickKids Foundation's mission to transform care for every child.
"We're proud to support this important fundraising event to help children and their families in their time of need," said Joanne Dalziel, AVP National Product Portfolio at Co-operators General Insurance, who is a top-level corporate sponsor of Ride for SickKids for the second year. "The funds raised each year by the Ride for SickKids is used to purchase life-saving pediatric equipment that is so vital to the work the passionate and dedicated team at SickKids do every day."
One of the largest charity rides in the GTA, the Ride for SickKids has raised more than $1.3 million since it began in 2009. This year's event will feature a scenic 100 km escorted ride through York Region, followed by a post-ride celebration with live entertainment, food & drinks, vendors and the raffle draw for prizes and the main prize of a 2025 custom built motorcycle by Cycleworx.
Honouring Two Brave Ambassador Children
Each year, the Ride honours children whose courageous journeys at SickKids inspire our community to give back. This year, we are proud to spotlight two ambassador children:
Ilaria, now 18, was just 12 when she was diagnosed with the rare disorder Langerhans Cell Histiocytosis (LCH). The condition caused a lesion in her skull and excruciating migraines. "It was a scary and uncertain time," she recalls. "But my doctors at SickKids made all the difference." With the help of the oncology team, Ilaria began her road to healing. Her strength and grace through adversity continues to inspire others.
Baby Valentina was born on March 6, 2024, and within days was transferred to SickKids from Brampton Civic Hospital when doctors discovered serious complications. She was ultimately diagnosed with Rubinstein-Taybi Syndrome Type 2 and Ponto Cerebellar Hypoplasia, rare neurological conditions requiring specialized, ongoing care. Her family has been on an emotional journey of discovery, strength, and advocacy — made possible by the unmatched support of SickKids.
"These stories remind us why we ride," said Nella Figliano, Chair of the Ride for SickKids. "Each dollar raised goes directly toward helping kids like Ilaria and Valentina get the care they need. Their strength fuels our mission."
A Day of Community and Celebration
The Ride begins with a mass police-escorted departure at 11 a.m., and returns to North Maple Regional Park by 12:30 p.m. There, the celebration continues with lunch, live music, vendors, and many emotional moments: the grand prize motorcycle raffle draw at 2 p.m.
Media personality Stella Acquisto returns as this year's hosts, ensuring the day is filled with energy, connection, and purpose.
Event Details:
WHERE: North Maple Regional Park, 11085 Keele Street, Maple, ON
WHEN: Sunday, August 10, 2025
Riders arrive: 8 a.m.
Opening remarks & ambassador stories: 10:15 a.m.
Ride departs: 11 a.m.
Celebration & lunch: 12:30 p.m.
Raffle draw: 2 p.m.
About Co‑operators
Proudly Canadian since 1945, Co‑operators is a leading financial services co-operative, offering multi-line insurance and investment products, services, and personalized advice to help Canadians build their financial strength and security. With more than $74 billion in assets under administration, Co‑operators is well known for its community involvement and its commitment to sustainability. Currently a carbon neutral organization, Co-operators is committed to net-zero emissions in its operations and investments by 2040, and 2050, respectively. Co‑operators is recognized as one of Canada's Top 100 Employers and ranked as one of Corporate Knights' Best 50 Corporate Citizens in Canada. For more information, please visit: www.cooperators.ca.
For more information, please contact:
Nella Figliano, Chair
[email protected]
416-895-5215
www.rideforsickkids.com
Media Inquiries – Co-operators
[email protected]
SOURCE The Co-operators Group Limited
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
15 minutes ago
- Cision Canada
Health Canada Has Authorized CSL's ANDEMBRY® (garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (HAE) Français
ANDEMBRY is the first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks in people with HAE The authorization of ANDEMBRY expands CSL's HAE franchise and underscores the company's commitment to delivering innovative medicines to the HAE community OTTAWA, Canada, Aug. 8, 2025 /CNW/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced that Health Canada has granted a marketing authorization for ANDEMBRY ® (garadacimab) for routine prevention of attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. ANDEMBRY is a monoclonal antibody designed to target activated FXII (FXIIa), a plasma protein at the top of the HAE cascade that plays a key role in attacks of swelling in people with HAE. ANDEMBRY reinforces CSL's decades-long commitment to advancing innovation for the HAE community and is authorized with a prefilled pen for subcutaneous self-injection. "As the first monoclonal antibody discovered and developed entirely by CSL, ANDEMBRY is a reflection of our commitment to delivering innovative treatment options for the patients who need them most," said Bill Mezzanotte, MD, Executive Vice President, Head of R&D, CSL. "This approval marks a major step forward in HAE care, building on our more than 40-year legacy in HAE research and treatment optimization to offer people living with this life-threatening condition long-term control over their disease along with a convenient administration method." HAE is a rare, chronic, and potentially life-threatening genetic disorder characterized by recurrent and unpredictable attacks of angioedema. Attacks of HAE are often painful and can affect multiple sites of the body, including the abdomen, larynx, face, and extremities. ANDEMBRY inhibits the top of the HAE cascade while other HAE therapies target downstream mediators. "Health Canada's authorization of ANDEMBRY represents a significant advancement in the treatment of HAE," said Dr. Stephen Betschel, Chair of the Canadian Hereditary Angioedema Network. "This new therapy, which targets factor XIIa, offers a promising approach to preventing HAE attacks. By addressing the underlying mechanisms of HAE, ANDEMBRY provides an important option for patients to reduce the frequency of their attacks of angioedema. Having a new treatment option will further enhance our ability to help our patients manage their HAE effectively." The Health Canada authorization is based on data from the pivotal placebo-controlled Phase 3 VANGUARD trial evaluating the efficacy and safety of ANDEMBRY. The pivotal study (The Lancet, April 2023) demonstrated that treatment with ANDEMBRY: Reduced HAE attacks by a median of more than 99 percent and a reduced least squares mean of 89.2 percent, compared to placebo. Led to 62 percent of ANDEMBRY-treated patients remaining attack-free throughout the treatment period. The most common adverse reactions in the pivotal trial were injection site erythema, injection site bruising, injection site pruritus, injection site urticaria, headache, and abdominal pain. A published interim analysis (Allergy, Oct 2024) of the ongoing open-label extension study (median ANDEMBRY exposure of 13.8 months) showed that ANDEMBRY has a favorable long-term safety profile and provides sustained reductions in HAE attacks. "We are pleased to see Health Canada's authorization of ANDEMBRY for HAE and look forward to its availability in Canada," said Michelle Cooper, President, HAE Canada. "As the first treatment to target the top of the HAE cascade, this therapy represents a significant advancement in preventing HAE attacks. We believe it will provide meaningful benefits to the HAE community in Canada." This regulatory approval for ANDEMBRY is another crucial step in building toward the global availability of ANDEMBRY, which was recently approved in Australia, the United Kingdom (UK), the European Union (EU), Japan, Switzerland, and the United States (US). About HAE HAE is a rare and potentially life-threatening genetic condition that occurs in about 1 in 10,000 to 1 in 50,000 people. HAE is caused by deficient or dysfunctional C1-INH, a protein in the blood that helps to control inflammation. Inadequate amounts of properly functioning C1-INH can lead to the accumulation of fluid in body tissues, causing considerable swelling referred to as angioedema. HAE attacks can affect many parts of the body, including the face, abdomen, larynx, and extremities. Patients who have abdominal attacks of HAE can experience extreme pain, diarrhea, nausea, and vomiting caused by swelling of the intestinal wall. HAE attacks that involve the face or throat can result in airway closure, asphyxiation and, if left untreated, death. About ANDEMBRY ANDEMBRY is a novel monoclonal antibody inhibiting factor XIIa (anti-FXIIa mAb) that has completed the Phase 3 pivotal study as a once-monthly subcutaneous prophylactic treatment for attacks related to HAE, a form of bradykinin-mediated angioedema. ANDEMBRY is CSL's first homegrown recombinant monoclonal antibody to gain Health Canada approval. It was discovered and optimized by scientists at CSL's Bio21-based research site, with formulation and manufacturing for the clinical programs completed at the CSL Broadmeadows Biotech Manufacturing Facility. ANDEMBRY uniquely inhibits the plasma protein, FXIIa. FXII is the first protein activated in the HAE pathway, initiating the cascade of events leading to an HAE attack. By targeting activated FXII (FXIIa), ANDEMBRY inhibits this cascade at the top as compared to other HAE therapies that target downstream mediators. About t he VANGUARD Trial The multicenter, randomized, double-blind, parallel-group VANGUARD trial evaluated the efficacy and safety of ANDEMBRY, a first-in-class monoclonal antibody, as a prophylactic treatment for patients with hereditary angioedema. Patients aged 12 years and older with HAE type I or II underwent screening and a run-in study period to verify a baseline attack rate. Patients were randomized 3:2 to receive a loading dose of 400 mg followed by 200 mg of ANDEMBRY monthly (n=39) or volume matched placebo monthly (n=25) subcutaneously. After the six-month treatment period, patients were given the opportunity to continue into the open-label extension study, which is currently ongoing. The ongoing open-label extension of the Phase 3 VANGUARD study is evaluating the long-term safety and efficacy of ANDEMBRY (200 mg monthly) for the prophylactic treatment of hereditary angioedema attacks. Important Information for Canada For more information and a complete risk/benefit profile, please refer to the Product Monograph available here. About CSL CSL (ASX:CSL; USOTC:CSLLY) is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat Hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For more information about CSL, visit Media Contact Valerie Bomberger, CSL Office: +1 610-291-5388 Mobile: +1 267-280-3829 Email: [email protected] Etanjalie Ayala CSL Behring Mobile: +1 610 297 1069 Email: [email protected] Greg Healy CSL Mobile: +1 610-906-4564 Email: [email protected] In Australia: Kim O'Donohue CSL Mobile: +61 449 884 603 Email: [email protected] Brett Foley CSL Mobile: +61 461 464 708 Email: [email protected] Investors Contact Chris Cooper CSL Email: [email protected] +61 455 022 740 SOURCE CSL
Cision Canada
15 hours ago
- Cision Canada
Sun Life Announces Appointment of David Healy as incoming President of Sun Life U.S. Français
TORONTO, Aug. 7, 2025 /CNW/ - Kevin Strain, President and Chief Executive Officer of Sun Life is pleased to announce that David Healy, currently President of the Dental business at Sun Life U.S., will become the new President of Sun Life U.S. effective September 1, 2025. Mr. Healy succeeds Dan Fishbein, M.D., who announced his intention to retire in March 2026. Mr. Fishbein will assume the title of Executive Chair, Sun Life U.S. and will work with Mr. Healy to transition the leadership of the business. "Under Dan's leadership, our U.S. business has transformed over the past 11 years into a leader in health-related benefits and services that connect to the broader healthcare ecosystem and help people access the care and coverage they need. I want to thank Dan for his many contributions to Sun Life and we wish him all the best as he embarks on his next chapter," said Kevin Strain, President & CEO, Sun Life. "We're excited to have David join the Sun Life Executive Team and I am confident that David's broad experience and business acumen will help drive the next steps in our U.S. strategy. His combination of technology and operations experience and his employee benefits background are perfectly aligned to our ambitions for the U.S. business." Prior to his current role, Mr. Healy led the Group Benefits business for seven years, with a growth mindset focused on investing in new capabilities and services to make benefits easier for Clients and broadening access to care. His more than 20 years at Sun Life include leading the U.S. Operations and Technology teams, where he combined services across business units for consistency in the Client experience and modernized IT delivery. He also oversaw the integration of Assurant Employee Benefits (AEB), which Sun Life acquired in 2016, and was instrumental in the acquisition of Insurtech Maxwell Health in 2018, which added digital talent and expertise to the organization. Prior to joining Sun Life, Mr. Healy held roles at Keyport Life Insurance Company and Manulife Financial. He graduated from Providence College, where he received a Bachelor of Science in marketing and holds an MBA, high honors, from Boston University. About Sun Life Sun Life is a leading international financial services organization providing asset management, wealth, insurance and health solutions to individual and institutional Clients. Sun Life has operations in a number of markets worldwide, including Canada, the U.S., the United Kingdom, Ireland, Hong Kong, the Philippines, Japan, Indonesia, India, China, Australia, Singapore, Vietnam, Malaysia and Bermuda. As of June 30, 2025, Sun Life had total assets under management of $1.54 trillion. For more information, please visit Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE) and Philippine (PSE) stock exchanges under the ticker symbol SLF.
Cision Canada
16 hours ago
- Cision Canada
Access to multiple sclerosis (MS) treatments inadequate in British Columbia
VANCOUVER, BC, Aug. 7, 2025 /CNW/ - Teresa Alfeld, a filmmaker who was recently diagnosed with multiple sclerosis (MS), is calling for the provincial government to fund a medication that is available in every other province in Canada – but not BC. Teresa was diagnosed with MS in 2024, 20 years after her Type 1 diabetes diagnosis. Because of her diabetes, she was recommended to treat her MS with ofatumumab (Kesimpta), because some of the other available treatments for MS could worsen her Type 1 diabetes. Hower, this medication is not covered by PharmaCare. BC is the only province in Canada that does not provide public coverage for Health Canada-approved, anti-CD20 therapies for relapsing MS – ofatumumab (Kesimpta) and ocrelizumab (Ocrevus). "My diagnosis was a gut-punch. After years of hard work building my filmmaking career, my future was suddenly in jeopardy," says Teresa. "On top of processing this life-changing diagnosis, I've had to fight for access to ofatumumab, a drug that I could easily access if I lived anywhere else in Canada." Ofatumumab is the only monoclonal antibody available as a subcutaneous self-injection rather than being delivered via infusion at a specialty clinic. This fills a significant gap in MS treatment for persons with MS who are recommended to be treated with a high-efficacy monoclonal antibody, like Teresa. Funding high-efficacy medications reduces the financial burden to health and social systems through fewer MS relapses requiring hospitalization and loss of employment. According to the Conference Board of Canada, as disability from MS worsens, costs incurred outside the health care system, such as informal care and productivity losses, continue to increase until they comprise two-thirds of all health costs. The appropriate use of disease-modifying therapies (DMTs) can provide significant health and economic benefits to people living with MS. Teresa and her family are now considering moving out of the province so she can access ofatumumab to manage her MS. "Not having access to Kesimpta doesn't just affect my health – it affects my ability to plan ahead and build a stable life," says Teresa. "This is an equity issue, plain and simple. I'm not asking for special treatment from the government, but for fair treatment for myself and every other British Columbian living with MS." MedAccessBC Urges Government to Take Action Teresa's story highlights a larger, systemic issue that the Medicines Access Coalition — BC (MedAccessBC) has been working to address for over two decades. MedAccessBC represents over 30 patient care organizations and advocates for fair, timely, and equitable access to medications for British Columbians. "People living with MS in BC should be able to access all Health Canada-approved treatments, which all other Canadians can access," says Don Bindon, co-chair of MedAccessBC. "MS is a disease that strikes people in the prime of their lives, and access to high-efficacy medications soon after diagnosis can delay disease progression. The provincial government should consider the productivity advantages of funding ofatumumab and ocrelizumab for relapsing MS." As a non-profit coalition, MedAccessBC continues to collaborate with patient communities, healthcare professionals, and policy makers to ensure that health decisions prioritize outcomes and do not compromise patient well-being in the name of cost containment. Call to Action MedAccessBC is urging the provincial government to approve and fund ofatumumab and ocrelizumab for relapsing MS through the BC PharmaCare program without further delay. Teresa's message to decision makers is simple: "While MS is unpredictable, treatment shouldn't be. I'm asking for the ability to manage my disease based on what works for me, not what PharmaCare happens to cover." About multiple sclerosis (MS) Canada has one of the highest rates of multiple sclerosis (MS) in the world. On average, 12 Canadians are diagnosed every day. MS is a neurological disease of the central nervous system (brain, spinal cord). Most people are diagnosed with MS between the ages of 20 and 49. MS is a continuous disease process that progresses through different stages over time, and everyone experiences it differently as severity, symptoms and response to treatment can vary from one person to the next. The unpredictable, episodic yet progressive nature of MS makes it particularly challenging to maintain an adequate quality of life. About the Medicines Access Coalition of BC: MedAccess BC advocates for improved access to medications and health technologies for individuals with chronic diseases. Representing over 30 patient organizations, it has been working since 1997 to improve access to evidence-based medicines through BC's PharmaCare program.
